Information Provided By: 
Fly News Breaks for February 12, 2019
RTRX
Feb 12, 2019 | 07:31 EDT
Canaccord analyst Michelle Gilson sees the recent weakness in Retrophin as offering an attractive buying opportunity into several first half catalysts. Specifically, she is looking to proof of concept data for CNSA-001 in PKU patients, April data from its SONAR study of atrasentan in diabetic neuropathy, and the June 30 PDUFA for a new formulation of Thiola. Gilson reiterated her Buy rating and $36 price target on Retrophin shares.
News For RTRX From the Last 2 Days
There are no results for your query RTRX
